Long-term remission with eculizumab in atypical haemolytic uraemic syndrome

被引：2

作者：

Carter, Simon ^{[1
]}

Hewitt, Ian ^{[4
]}

Kausman, Joshua ^{[1
,2
,3
]}

机构：

[1] Royal Childrens Hosp, Melbourne, Vic, Australia

[2] Murdoch Childrens Res Inst, Murdoch, WA, Australia

[3] Univ Melbourne, Melbourne, Vic, Australia

[4] Princess Margaret Hosp, Perth, WA, Australia

来源：

NEPHROLOGY | 2017年 / 22卷

关键词：

atypical haemolytic uraemic syndrome; eculizumab; long term outcome; paediatric; safety profile;

D O I：

10.1111/nep.12932

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The understanding of the role of complement dysregulation in atypical haemolytic uraemic syndrome (aHUS) has led to major changes in therapeutic approaches and outcomes. Eculizumab is a humanized anti-C5 monoclonal antibody that inhibits the terminal complement pathway and has revolutionized the treatment and prognosis of aHUS. However, published reports to date have had relatively short-term follow-up. We report two paediatric cases of aHUS successfully treated with eculizumab longer than 6years with no serious adverse events and preservation of renal function.

引用

页码：7 / 10

页数：4

共 13 条

[1] Success of eculizumab in the treatment of atypical hemolytic uremic syndrome [J].

Baskin, Esra ;

Gulleroglu, Kaan ;

Kantar, Asli ;

Bayrakci, Umut ;

Ozkaya, Ozan .

PEDIATRIC NEPHROLOGY, 2015, 30 (05) :783-789

[2] Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria [J].

Brodsky, Robert A. ;

Young, Neal S. ;

Antonioli, Elisabetta ;

Risitano, Antonio M. ;

Schrezenmeier, Hubert ;

Schubert, Jorg ;

Gaya, Anna ;

Coyle, Luke ;

De Castro, Carlos ;

Fu, Chieh-Lin ;

Maciejewski, Jaroslaw P. ;

Bessler, Monica ;

Kroon, Henk-Andre ;

Rother, Russell P. ;

Hillmen, Peter .

BLOOD, 2008, 111 (04) :1840-1847

[3] Long-term remission with eculizumab in atypical haemolytic uraemic syndrome [J].

Carter, Simon ;

Hewitt, Ian ;

Kausman, Joshua .

NEPHROLOGY, 2017, 22 :7-10

[4] Case Report: Benefits and Challenges of Long-term Eculizumab in Atypical Hemolytic Uremic Syndrome [J].

Cullinan, Noelle ;

Gorman, Kathleen Mary ;

Riordan, Michael ;

Waldron, Mary ;

Goodship, Timothy H. J. ;

Awan, Atif .

PEDIATRICS, 2015, 135 (06) :E1506-E1509

[5] The long-term outcomes of atypical haemolytic uraemic syndrome: a national surveillance study [J].

Durkan, Anne M. ;

Kim, Siah ;

Craig, Jonathan ;

Elliott, Elizabeth .

ARCHIVES OF DISEASE IN CHILDHOOD, 2016, 101 (04) :387-391

[6] Eculizumab hepatotoxicity in pediatric aHUS [J].

Hayes, Wesley ;

Tschumi, Sibylle ;

Ling, Simon C. ;

Feber, Janusz ;

Kirschfink, Michael ;

Licht, Christoph .

PEDIATRIC NEPHROLOGY, 2015, 30 (05) :775-781

[7] Pathology after Eculizumab in Dense Deposit Disease and C3 GN [J].

Herlitz, Leal C. ;

Bomback, Andrew S. ;

Markowitz, Glen S. ;

Stokes, M. Barry ;

Smith, R. Neal ;

Colvin, Robert B. ;

Appel, Gerald B. ;

D'Agati, Vivette D. .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 23 (07) :1229-1237

[8] The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria [J].

Hillmen, Peter ;

Young, Neal S. ;

Schubert, Joerg ;

Brodsky, Robert A. ;

Socie, Gerard ;

Muus, Petra ;

Roeth, Alexander ;

Szer, Jeffrey ;

Elebute, Modupe O. ;

Nakamura, Ryotaro ;

Browne, Paul ;

Risitano, Antonio M. ;

Hill, Anita ;

Schrezenmeier, Hubert ;

Fu, Chieh-Lin ;

Maciejewski, Jaroslaw ;

Rollins, Scott A. ;

Mojcik, Christopher F. ;

Rother, Russell P. ;

Luzzatto, Lucio .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (12) :1233-1243

[9] Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival [J].

Kelly, Richard J. ;

Hill, Anita ;

Arnold, Louise M. ;

Brooksbank, Gemma L. ;

Richards, Stephen J. ;

Cullen, Matthew ;

Mitchell, Lindsay D. ;

Cohen, Dena R. ;

Gregory, Walter M. ;

Hillmen, Peter .

BLOOD, 2011, 117 (25) :6786-6792

[10] Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies [J].

Licht, Christoph ;

Greenbaum, Larry A. ;

Muus, Petra ;

Babu, Sunil ;

Bedrosian, Camille L. ;

Cohen, David J. ;

Delmas, Yahsou ;

Douglas, Kenneth ;

Furman, Richard R. ;

Gaber, Osama A. ;

Goodship, Timothy ;

Herthelius, Maria ;

Hourmant, Maryvonne ;

Legendre, Christophe M. ;

Remuzzi, Giuseppe ;

Sheerin, Neil ;

Trivelli, Antonella ;

Loirat, Chantal .

KIDNEY INTERNATIONAL, 2015, 87 (05) :1061-1073

← 1 2 →